Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
IND for DF-003 Cleared by FDA for ROSAH Syndrome Trial
In a significant development for the medical community, Drug Farm announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application of DF-003. This novel drug, hailed as a first-in-class oral medication,…
Merck & Co Nears $1.3 Billion Acquisition of Eyebiotech
Merck & Co, a global pharmaceutical giant, has finalized a monumental deal worth $3 billion to acquire EyeBio, a leading developer of eye-focused drugs. The agreement includes an upfront payment of $1.3 billion in cash, along with an additional $1.7 billion…
USC Roski Eye Institute Investigates Promising Drugs for TED
The USC Roski Eye Institute is making significant strides in the realm of Thyroid Eye Disease (TED) treatment through pioneering clinical trials exploring new medications. TED, a condition characterized by bulging eyes and potential vision impairment, has traditionally necessitated multiple…
Exonate Adds Dr. Rafiq Hasan to Leadership Team
Exonate announced the expansion of its Board with the appointment of Dr. Rafiq Hasan as Non-Executive Director. This strategic move aims to bolster the company’s expertise in ophthalmology, particularly within the diabetic eye disease sector, as it advances its lead…
Exclusive Interview with Prof. Dr. Oliver Findl
*If you are interested in becoming a part of our OBN Spotlight TV series, reach us at info@ophthalmologybreakingnews.com. Q1: As you reflect on the recent ESCRS 2023 Congress, could you share with us the key highlights and breakthroughs in cataract…
Outlook Therapeutics Seeks UK Approval for Wet AMD Drug
Outlook Therapeutics announced the submission of its Marketing Authorisation Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) in a press release. The MAA is for bevacizumab gamma (ONS-5010/LYTENAVA), its investigational formulation of bevacizumab for the…
Rezolute’s Phase 2 Success with Oral DME Drug
Rezolute announced promising topline results from its Phase 2 clinical study of RZ402. This study targeted patients with diabetic macular edema (DME) who were either naïve to or had limited exposure to anti-vascular endothelial growth factor (anti-VEGF) injections. Monumental Results…
KDB GLIDE FDA 510(k) Clearance for Expanded Glaucoma Use
New World Medical announced a significant milestone with the receipt of 510(k) indication expansion from the U.S. Food and Drug Administration (FDA) for KDB (Kahook Dual Blade) GLIDE. This clearance allows for the reduction of intraocular pressure (IOP) in adult…
Clearside Biomedical Publishes SCS Delivery Guidelines
Clearside Biomedical has taken a significant step forward in the field of ophthalmology by publishing new guidelines for suprachoroidal space (SCS) injection, a technique used to deliver medication directly to the back of the eye. These guidelines have been featured…
China Grants Priority Review for Innovent’s TED Treatment NDA
Innovent Biologics announced that its New Drug Application (NDA) for their recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, IBI311, has been accepted and granted priority review designation by the Center for Drug Evaluation (CDE) of the China National Drug…